Richard Scalzo - Jul 5, 2022 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role
Vice President of Accounting and Administration and Treasurer
Signature
/s/ Richard Scalzo
Stock symbol
DYN
Transactions as of
Jul 5, 2022
Transactions value $
$0
Form type
4
Date filed
7/6/2022, 06:23 PM
Previous filing
Jun 15, 2022
Next filing
Jul 13, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DYN Stock Option (right to buy) Award $0 +17.3K $0.00 17.3K Jul 5, 2022 Common Stock 17.3K $5.54 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved.

Remarks:

Vice President of Accounting and Administration and Treasurer